LexDanaLexDanabeta
Inventor

MAXINE BAUZON

Inventor
US

Overview

5→
Patents
2022–2026
Patent span
Human necessities
Primary field (CPC A)

Patents· 5 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%
C07KPeptides19%
C12NMicroorganisms or enzymes14%
C12YEnzymes10%
Y02ATechnologies for adaptation to climate change10%
A61NElectrotherapy5%
PatentTitleYear
12,595,314Antibody specific for GPC3 and methods of use thereof202612,527,836Gla domains as targeting agents202611,981,723Method of targeting exosomes202411,970,546Antibody specific for Mucin-1 and methods of use thereof202411,530,401Short-acting Factor VII polypeptides2022

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2022Patents assigned to COAGULANT THERAPEUTICS CORP (1)· patent assignee history
2022–2026Based in US· patent location history
2024–2026Patents assigned to GLADIATOR BIOSCIENCES INC (2)· patent assignee history
2024Patents assigned to SCHERER TECHNOLOGIES LLC R P (1)· patent assignee history
2026Patents assigned to R P SCHERER TECH LLC (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
GLADIATOR BIOSCIENCES INC22024–2026
COAGULANT THERAPEUTICS CORP12022
R P SCHERER TECH LLC12026
SCHERER TECHNOLOGIES LLC R P12024
Locations
LocationPatentsSpan
US52022–2026